<unk> , sold under the brand name Rubraca, is a PARP inhibitor used as an anti-cancer agent.<unk>  is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1). It is approved in the United States and in Europe as third line treatment in BRCA-mutated ovarian cancer. It can be taken orally in tablet form. The most common side effects include tiredness or weakness, nausea (feeling sick), increased levels of creatinine (which may indicate kidney problems) and liver enzymes in the blood (which may indicate liver damage), vomiting, anaemia (low red blood cell counts), decreased appetite, dysgeusia (taste disturbances), diarrhoea, thrombocytopenia (low levels of platelets) and abdominal pain (belly ache).
Rucaparib
Olaparib
Decitabine
Zalcitabine
Martinostat
Apricitabine
Trifluridine
Panobinostat